JACC
HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
QUICK SEARCH:   [advanced]


     

J Am Coll Cardiol, 2005; 45:1574-1579, doi:10.1016/j.jacc.2005.01.048
© 2005 by the American College of Cardiology Foundation
This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (81)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Aoki, J.
Right arrow Articles by Kutryk, M. J.B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Aoki, J.
Right arrow Articles by Kutryk, M. J.B.

Endothelial Progenitor Cell Capture by Stents Coated With Antibody Against CD34

The HEALING-FIM (Healthy Endothelial Accelerated Lining Inhibits Neointimal Growth-First In Man) Registry

Jiro Aoki, MD*, Patrick W. Serruys, MD, PhD, FACC*,*, Heleen van Beusekom, MD, PhD*, Andrew T.L. Ong, MBBS, FRACP*, Eugene P. McFadden, MBChB, MD, FRCPI, FACC*, Georgios Sianos, MD, PhD*, Willem J. van der Giessen, MD, PhD*, Evelyn Regar, MD, PhD*, Pim J. de Feyter, MD, PhD, FACC*, H. Richard Davis, MSc{dagger}, Stephen Rowland, PhD{dagger} and Michael J.B. Kutryk, MD, PhD{ddagger}

* Thoraxcenter, Erasmus Medical Center, Rotterdam, the Netherlands
{dagger} OrbusNeich, Fort Lauderdale, Florida
{ddagger} Terrence Donnelly Heart Centre, St. Michael’s Hospital, University of Toronto, Toronto, Canada



View larger version (53K):

[in a new window]
  		Figure 1 Endothelial progenitor cell (EPC) capture coating technology.

 


View larger version (113K):

[in a new window]
  		Figure 2 Overview (A) and details (left: B, C; mid: D, E; right: F) of the atherectomy specimen obtained six months following stent placement. Histology shows a mixture of myxoid (B, C) and fibrous material (F) consisting of smooth muscle cells (C, E) within variable amounts of extracellular matrix. Some fragments contained thrombus remnants (Th) (D, E) and calcifications (Ca) (F). A = elastin stain; B, D, F= hematoxylin eosin; C, E = immunocytochemistry for smooth muscle cell-specific alpha actin.

 


View larger version (14K):

[in a new window]
  		Figure 3 Endothelial progenitor cell capture stent bioactivity (in vitro). The cell-binding activity of the HEALING-FIM and HEALING-II stents was compared with negative controls (bare stents). In the bioassay, stents were exposed to a suspension of human CD34+ cells (kg-1a cells, American Type Culture Collection) for 1 h with agitation. Excess cells are removed and bound cells are tagged with a fluorescent nuclear stain (DAPI, 4'6-diamidino-2-phenylindole). After rinsing, the stents were placed in a microplate for analysis in a fluorescent plate reader. The number of cells bound was calculated by interpolation from standard curve on the same plate.

 




HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
Copyright © 2005 by the American College of Cardiology Foundation.